The Manufacturers Life Insurance Company Invests $250,000 in Monopar Therapeutics Inc. $MNPR

The Manufacturers Life Insurance Company bought a new stake in Monopar Therapeutics Inc. (NASDAQ:MNPR) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 4,572 shares of the company’s stock, valued at approximately $250,000.

A number of other institutional investors have also added to or reduced their stakes in MNPR. Goldman Sachs Group Inc. bought a new position in Monopar Therapeutics in the first quarter worth approximately $673,000. Jane Street Group LLC bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $377,000. Geode Capital Management LLC raised its position in shares of Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after purchasing an additional 48,379 shares during the period. JPMorgan Chase & Co. raised its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. Finally, Rhumbline Advisers bought a new position in shares of Monopar Therapeutics in the 2nd quarter worth $209,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Trading Up 3.1%

Shares of NASDAQ:MNPR opened at $116.49 on Tuesday. The stock has a market cap of $781.65 million, a PE ratio of -53.68 and a beta of 1.47. The stock’s fifty day simple moving average is $97.23 and its two-hundred day simple moving average is $71.85. Monopar Therapeutics Inc. has a 1-year low of $29.18 and a 1-year high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, sell-side analysts forecast that Monopar Therapeutics Inc. will post -2.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. BTIG Research boosted their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Barclays reissued an “overweight” rating and set a $128.00 target price (up from $125.00) on shares of Monopar Therapeutics in a research report on Thursday. Finally, Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Monopar Therapeutics has an average rating of “Moderate Buy” and an average target price of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.